levels were measured after AMC-HN9 (wild-type p53) and UMSCC-1 cells (p53-null) were exposed to PL for 1 h and 3 h with or without 3 mM NAC pretreatment for 1 h. The error bars represent s.d. from three independent experiments, each performed with triplicate samples. * denotes p < 0.001 relative to control. (B) ROS elevation by PL and prevention of the effect by NAC or catalase. AMC-HN9 or UMSCC-1 cells were exposed to 10 µM PL or DMSO (basal) for 1 h and 3 h. Cells were also pretreated with NAC (3 mM) for 1 h or catalase (CAT, 2,000 UmL -1 ) for 2 h before exposure to PL (10 µM) for 3 h. ROS levels were measured by flow cytometry using DCF-DA and are shown as fold changes over DMSO-treated (basal) Apoptosis assays in AMC-HN9 cells exposed to PL. Cells were exposed to PL for 48 h, and the annexin V-positive apoptotic fractions were measured. *, ** denote p < 0.01 relative to control and 10 µM PL, respectively. Cells were also pretreated with 3 mM NAC for 1 h or 2 µM of the PARP inhibitor 4-amino-1,8-naphthalimide (4-ANI) for 16 h before being exposed to PL 10 µM. Quantification from in situ TUNEL assay in tumor sections from each group. TUNEL-positive apoptotic bodies were counted blindly in 10 randomly selected high-powered fields. The error bars represent standard errors. Two-tailed Student's t-test, * denotes p < 0.01.
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